Interleukin-12 cDNA skin transfection potentiates human papillomavirus E6 DNA vaccine-induced antitumor immune response.
Human papillomaviruses are associated with >90% of all cases of uterine cervical tumors. The E6 and E7 oncoproteins of human papillomavirus are potentially ideal targets of immune therapy for cervical cancer, because their expression is necessary for cellular transformation. Although both E6 and E7 proteins contain numerous predicted cytotoxic T lymphocyte (CTL) epitopes that are capable of binding to human leukocyte antigens, the majority of earlier in vivo tumor rejection studies have focused on E7. We show here that gene gun-mediated skin transfection of plasmid vector encoding the nontransforming, amino-terminal half of E6 resulted in the induction of E6-specific CTL activity and tumor rejection in a murine model. The use of recombinant murine interleukin-12 (rmIL-12) as a vaccine adjuvant has been shown to result in both an enhancement and suppression of immune responses, depending upon the doses of rmIL-12 and the experimental systems used. We demonstrate here that local expression of transgenic mIL-12 at the E6 DNA vaccination site potentiated E6-specific CTL responses and increased vaccine-induced antitumor therapeutic efficacy. Our results indicate that transfection of the mIL-12 gene at the vaccination site may represent an attractive adjuvant for cancer gene immunotherapy.
H. Lee Moffitt Cancer Center and Research Institute, and Department of Medical Microbiology and Immunology, University of South Florida, College of Medicine, Tampa 33612, USA.
J
J
Tan
N S
NS
Yang
J G
JG
Turner
G L
GL
Niu
H F
HF
Maassab
J
J
Sun
M L
ML
Herlocher
A E
AE
Chang
H
H
Yu
D000818:Animals; D019496:Cancer Vaccines / Q000627:therapeutic use; D018076:DNA, Complementary; D005260:Female; D005822:Genetic Vectors; D006801:Humans; D018664:Interleukin-12 / Q000235:genetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D009856:Oncogene Proteins, Viral / Q000235:genetics*; D053918:Papillomavirus Vaccines; D012097:Repressor Proteins; D012867:Skin / Q000378:metabolism*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014162:Transfection; D002583:Uterine Cervical Neoplasms / Q000276:immunology / Q000628:therapy*; D019444:Vaccines, DNA / Q000627:therapeutic use*; D014765:Viral Vaccines / Q000627:therapeutic use
D019496:Cancer Vaccines; D018076:DNA, Complementary; C068651:E6 protein, Human papillomavirus type 16; D009856:Oncogene Proteins, Viral; D053918:Papillomavirus Vaccines; D012097:Repressor Proteins; D019444:Vaccines, DNA; D014765:Viral Vaccines; D018664:Interleukin-12